AI assistant

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

Jade Biosciences, Inc. Director's Dealing 2021

Jun 30, 2021

33383_dirs_2021-06-29_129ce7ae-6fbc-45f3-9db5-1c210f04d22d.zip

Director's Dealing

Open in viewer

Opens in your device viewer

SEC Form 3 — Initial Statement of Beneficial Ownership

Issuer: Aerovate Therapeutics, Inc. (AVTE)
CIK: 0001798749
Period of Report: 2021-06-29

Reporting Person: NOYES TIMOTHY P (Director, Chief Executive Officer)

Holdings (Derivative)

Security	Exercise Price	Expiration	Underlying	Shares	Ownership
Stock Option (Right to Buy)	$2.144	2031-04-01	Common Stock (254253)		Direct
Stock Option (Right to Buy)	$2.144	2031-04-01	Common Stock (493381)		Direct

Footnotes

F1: 25% of this option shall vest and become exercisable on February 15, 2022, with the remainder vesting in 36 substantially equal monthly installments thereafter.

F2: 25% of this option shall vest and become exercisable on June 4, 2022, with the remainder vesting in 36 substantially equal monthly installments thereafter.